sur XSENSIO
Xsensio SA Secures $7M to Advance Biosensing Technology
Xsensio SA, a Swiss deep-tech company, has successfully closed a $7M oversubscribed Series A financing round. Leading the round was WI Harper, alongside Privilège Ventures and additional investors from the US, Europe, and Asia. The influx of capital is set to expedite the development and clinical validation of Xsensio's Lab-on-Skin© wearable biosensing platform.
This platform aims to provide continuous dynamic biochemical data, supporting clinical decision-making beyond hospital settings. Xsensio's CEO, Esmeralda Megally, emphasizes the potential impact of real-time biochemical monitoring on patient care, offering data previously unavailable at the point of care.
Additionally, a collaboration with Texas Instruments has been announced to enhance Xsensio's semiconductor technology capabilities, promising reliability and cost-effective deployment.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de XSENSIO